THE RATIO OF CD-68+ AND CD-163+ MACROPHAGES IN ENDOMETRIAL ENDOMETRIOID CARCINOMA
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-2-2022-g.10575Keywords:
CD68+ and CD163+ macrophages, endometrial endometrioid carcinoma, ERα, microvessel density, Кі-67Abstract
Aim: to evaluate the localization and content of CD163+ and CD68+ macrophages in endometrial endometrioid carcinoma (EEC) considering the clinicopathological characteristics of tumor progression. Object and methods: surgical samples of 65 patients with I–II stage endometrial cancer aged from 32 to 78 years (average age 58.3±1.9 years). Methods: clinical, morphological, immunohistochemical. Results: the heterogeneity of CD68+ and CD163+ macrophage subpopulations in the EEC was detected both in the tumor niche and in stromal microenvironment. It was shown that the expression of estrogen receptor α (71.9±5.6%) and the cell proliferation marker Ki-67 (55.3±4.6%) increases in the stromal component of EEC with a high content of CD163+ macrophages compared to the expression of these biomolecular markers (respectively 43.4±4.2 and 38.0±3.4%, p <0.05) in EEC with the low content of CD163+ macrophages. The ratio of stromal CD163+-/CD68+-macrophages in the poorly differentiated EEC or in the tumor with deep myometrial invasion or with the high microvessel density was 2.6, 3.5, and 3.5, respectively. This ratio was smaller in EEC with a lower malignant potential (G2-tumors, tumor invasion <1/2 of myometrium, low high microvessel density) — 1.8, 1.4, and 1.7. Conclusions: an increase in the content of CD163+-macrophages with a simultaneous decrease in the number of CD68+-macrophages in the stromal component of EEC is associated with such indicators of neoplasm progression as a low degree of differentiation, deep myometrial invasion, high proliferative and angiogenic potential. The obtained results should be considered when choosing the treatment strategy for endometrial cancer patients depending on the polarization of macrophages.
References
Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol 2018; 8:49. doi.org/10.3389/fonc.2018.000493.
Najafi M, Gorade NH, Farhood B, et al. Macrophage polarity in cancer: A review. |J Cell Biochem 2019; 120 (3): 2756–65. doi: 10.1002/jcb.27646.
Karaman ОМ, Ivanchenko AV, Chekhun VF. Macrophages — a perspective target for antineoplastic immunotherapy. Exp Oncol 2019; 41 (4): 282–90.
Zhou K, ChengT, Zhan J, et al. Тargeting tumor-associated macrophages the tumor microenvironment (Review). Oncol Lett 2020; 20 (5): 234. doi: 10.3892/ol.2020.12097.
Owen JL, Mohamadzadeh M. Macrophages and chemokines as mediators of angeogenesis. Front Physiol 2013; 4: 159.
Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The emerging role of the microenvironment in endometrial cancer. Cancers 2018; 10: 408; doi:10.3390/cancers10110408.
Aikian AZ, Shynkevych VI, Kaidashev IP. Quantitative assessment of CD68+ and CD163+ macrophages in the primary focus and metastatic lesions of regional lymph nodes in non-luminal her2-positive invasive breast carcinoma. Wiadomosci Lekarskie 2019; 72 (10): 1861–5.
Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomedical Science 2019; 26: 78 https://doi.org/10.1186/s12929-019-0568-z.
Jackute J, Zemaitis M, Pranys D, et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunology 2018; 19: 3. doi 10.1186/s12865-018-0241-4.
Jamiyan T, Kuroda H, Yamaguchi R, et al. CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast.Virchows Arch 2020; 477 (6): 767–75. doi: 10.1007/s00428-020-02855-z.
Kelly MG, Francisco AMC, Cimic A, et al. Type 2 endometrial cancer is associated with a high density of numor-associated macrophages in the stromal compartment. Reprod Sci 2015; 22 (8): 948–53. doi: 10.1177/1933719115570912.
Kübler K, Ayub TH, Weber SK, et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol 2014; 135 (2): 176–83. doi: 10.1016/j.ygyno.2014.08.028.
Ning Ch, Xie B, Zhang L, et al. Infiltrating macrophages induce ERα expression through an IL17A-mediated epigenetic mechanism to sensitize endometrial cancer cells to estrogen. Cancer Res 2016; 76 (6): 1354–6 doi: 10.1158/0008-5472.CAN-15-1260.
Nesina I, Iurchenko N, Nespriadko S, Buchynska L. Tumor-associated macrophages, FOXP3+-lymphocytes and microvessel density in endometrial carcinoma of patients with various menstrual status. Oncology 2017; 19 (1):52–7 (in Ukrainian).
Nesina I, Iurchenko N, Nespriadko S, Buchynska L. Twist expression and content of tumour-associated macrophages in endometrial carcinoma. Oncol Clin Pract 2021; 17 (4): 139–47: doi: 10.5603/OCP.2021.0026.
Zinovkin DA, Pranol ZI, Bilsky IA, Zmushko VA. Tumor-associated t-lymphocytes and macrophages are decreased in endometrioid endometrial carcinoma with MELF-pattern stromal changes. Cancer Microenviron 2018; 11 (2–3): 107–14. doi: 10.1007/s12307-018-0213-5.
Buchynska LG, Movchan OM, Iurchenko NP. Expression of chemokine receptor CXCR4 in tumor cells and content of CXCL12+-fibroblasts in endometrioid carcinoma of endometrium. Exp Oncol 2021; 43 (2): 135–41: doi: 10.32471/exp-oncology.2312-8852.vol-43-no-2.16240.
Gunaydin G. CAFs Interacting with TAMs in tumor microevironment to enhance tumorigenesis and immune evasion. Front Oncol 2021; 11: 668349. doi: 10.3389/fonc.2021.668349.
Li C, Xu X, Wei S, et al. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer 2021; 9 (1): e001341. doi:10.1136/jitc-2020-001341.
